Candidate Strategies for Development of a Rapid-Acting Antidepressant Class That Does Not Result in Neuropsychiatric Adverse Effects: Prevention of Ketamine-Induced Neuropsychiatric Adverse Reactions

Candidate Strategies for Development of a Rapid-Acting Antidepressant Class That Does Not Result in Neuropsychiatric Adverse Effects: Prevention of Ketamine-Induced Neuropsychiatric Adverse Reactions

Non-competitive N-methyl-D-aspartate/glutamate receptor (NMDAR) antagonism has been considered to play important roles in the pathophysiology of schizophrenia. In spite of severe neuropsychiatric adverse effects, esketamine (racemic enantiomer of ketamine) has been approved for the treatment of conv...

Full description

Bibliographic Details
Main Authors: Motohiro Okada, Yasuhiro Kawano, Kouji Fukuyama, Eishi Motomura, Takashi Shiroyama
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:International Journal of Molecular Sciences
Subjects:
N-methyl-D-aspartate
schizophrenia
mood disorder
L-glutamate
GABA
catecholamine
Online Access:https://www.mdpi.com/1422-0067/21/21/7951

Similar Items

Similar Items